Ozempic and Wegovy Generics Arrive in Six Countries — But Portugal Must Wait Until 2031

Sources: Observador (Mar 21, 2026)

The pharmaceutical monopoly on Ozempic and Wegovy — the blockbuster diabetes and obesity medications that have reshaped global weight-loss treatment — ended this weekend in India, China, Brazil, Canada, Turkey, and South Africa. But Portugal, along with the rest of Europe and the United States, must wait until 2031 before generic versions can reach the market. For broader context, see the SPD/Ordem dos Médicos challenge to Infarmed's generic-prescription circular for glucose sensors.

Novo Nordisk's patent on semaglutide (the active ingredient in both drugs) expired March 22 in those six jurisdictions, opening the door for competing manufacturers to produce biosimilar versions that could cost 30 to 40 percent less than the branded originals. Indian regulators are expected to approve the first generics within days, and at least ten Chinese pharmaceutical companies have completed final-stage evaluations of their biosimilar candidates.

Why the Five-Year Wait for Europe?

Patent law varies by jurisdiction, and Novo Nordisk secured extended protection in the EU and US through mechanisms designed to reward pharmaceutical innovation. Those extensions delay generic competition until 2031, preserving the Danish company's monopoly pricing power in the world's wealthiest markets for another half-decade.

In Portugal, where Ozempic is subsidized by the national health system (SNS) but frequently in short supply, the delay has real consequences. Paula Freitas, president of the Portuguese Society of Endocrinology, Diabetes and Metabolism, told Observador that "a real piece of good news for Portugal will be when we can have the brand exist here in generic form."

Diabetes and obesity are both highly prevalent chronic diseases in Portugal, and demand for semaglutide-based treatments has surged. The medication is currently rationed through the SNS, with many patients unable to access it at all.

Price Impact Unlikely Before 2031

Some price relief could come sooner if the global surge in generic supply eases shortages and puts downward pressure on Novo Nordisk's pricing strategy. Ema Paulino, president of the National Association of Pharmacies (ANF), noted that Portugal's annual medication price reviews reference other European countries, so indirect effects are possible.

But the core dynamic is clear: as long as the patent holds in Europe, Novo Nordisk retains pricing power. The company has already moved preemptively in markets where the patent expired, cutting prices in China and Brazil and filing legal challenges in India to block biosimilar approvals.

Novo Nordisk told Observador that patent expiry is "a natural process in the lifecycle of a medication" and a stimulus to continue innovating. The company said it remains "confident in the robustness and scientific value of our portfolio" and expects to "maintain global leadership in the treatment of serious chronic diseases."

What Expats with Diabetes or Obesity Should Know

If you are managing diabetes or obesity in Portugal and considering semaglutide treatment, here's what the patent timeline means for you:

Until 2031: - Ozempic (for type 2 diabetes) remains under patent and is partially subsidized by the SNS for eligible patients. Supply shortages are common. - Wegovy (for obesity) is not widely available in Portugal and is expensive when obtained privately. - No legal generic or biosimilar versions will be sold in Portugal or elsewhere in the EU.

After 2031: - Biosimilar manufacturers will be able to produce competing semaglutide products, which typically cost 30–40% less than branded originals. - Increased supply should ease shortages and improve access through both the SNS and private pharmacies. - Portugal's regulatory agency (Infarmed) will evaluate biosimilar applications, a process that requires demonstrating therapeutic equivalence to the original drug.

International options: Importing medication from countries where generics are now legal (India, Brazil, Canada) is technically prohibited under Portuguese and EU pharmaceutical law, and quality/safety cannot be guaranteed for unapproved products.

The Bigger Picture: Biologics vs. Small-Molecule Drugs

Semaglutide is a biologic medication — a complex protein manufactured using living cells — not a traditional small-molecule drug. That makes biosimilar production significantly harder than copying a simple chemical compound.

As Paula Freitas explained, "Normal pills are simpler to replicate, because in this case the chemical structure [of injectable semaglutide] is much more complex." European regulators impose strict requirements on biosimilar manufacturers to prove equivalence in structure, purity, and clinical effect.

The upshot: even after 2031, biosimilar semaglutide won't flood the market overnight. Manufacturers will need regulatory approval, production capacity, and distribution networks. But the patent expiry is the critical first step.

For now, Portugal waits.

Related Articles: - Understanding Portugal's Healthcare System In Depth - Private Healthcare Costs in Portugal: What Expats Pay in 2026 - Cost of Living in Portugal: The Complete 2026 Breakdown. (Background: see our piece on the ANF-controlled Farminveste holding.)

Background: See the practical 2026 guide to using a Portuguese pharmacy.